Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro

Skin Pharmacology and Applied Skin Physiology

Volumn 11, Issue 1, 1998, Pages 43-51

  Wach, F ^a   Bosserhoff, A ^a   Kurzidym, U ^a   Nowok, K ^b   Landthaler, M ^a   Hein, R ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Fibroblasts; Glucocorticosteroids; Keratinocytes; Mometasone furoate

Indexed keywords

ANTIINFLAMMATORY AGENT; BETAMETHASONE VALERATE; CHEMOATTRACTANT; CLOBETASOL PROPIONATE; COLLAGEN GEL; COLLAGEN TYPE 1; CORTICOSTEROID; GLUCOCORTICOID; HYDROCORTISONE; MOMETASONE FUROATE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; FIBROBLAST; HUMAN; HUMAN CELL; KERATINOCYTE; LONG TERM CARE; MONOLAYER CULTURE; PRIORITY JOURNAL; SKIN ATROPHY; SKIN INFLAMMATION; SKIN INJURY; WOUND HEALING IMPAIRMENT;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; CELL DIVISION; CELLS, CULTURED; CHEMOTAXIS; COLLAGEN; FIBROBLASTS; GELS; GLUCOCORTICOIDS; HUMANS; KERATINOCYTES; PREGNADIENEDIOLS; SKIN;

EID: 0031750602     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029807     Document Type: Article

References (21)

1. Lee HJ, Taraporewala IB, Heiman AS: Anti-inflammatory steroids: Research trends and new compounds. Drugs Today 1989;25:577-588.
2. Zesch A: Lokaltherapie mit Kortikosteroiden: Grenzen der Anwendungsdauer. Hautarzt 1990;41:119-125.
3. Oikarinen A: Drugs acting on connective tissue: in Lapiere CM, Krieg T (eds): Connective tissue diseases of the skin. New York, Dekker, 1993, pp 361-375.
4. Oikarinen A, Autio P, Kiistala U: A new method to measure type I and III collagen synthesis in vivo: Demonstration of decreased collagen synthesis after lopical glucocorticoid treatment. J Invest Dermatol 1992; 98:220-225.
5. Koivukanges V, Karvonen J, RistelIi J, Oikarinen A: Topical mometasone furoate and betamethasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo. Br J Dermatol 1995;132:66-68.
6. Hein R, Korting HC, Mehring T: Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticosteroids on proliferation and chemotaxis of fibroblasts in vitro. Skin Pharmacol 1994;7:300-306.
7. Hein R, Mauch C, Hatamochi A, Krieg T: Influence of corticosteroids on chemotactic response and collagen metabolism of human skin fibroblasts. Biochem Pharmacol 1988;37:2723-2729.
8. Korting HC, Kerscher MJ, Schäfer-Korting M: Topical glucocorticoids with improved benefit/risk ratio: Do they exist? J Am Acad Dermatol 1992;27:87-92.
9. Popper TL, Gentles MJ, Kung TT, Berkenkopf J, Lutzky BN, Watnick AS, Shapiro EL: Structure-activity relationships of a series of novel topical corticosteroids. J Steroid Biochem 1987;27:837-843.
10. Shapiro EL. Gentles MJ, Tiberi L: 17-Heteroaroyl esters of corticosteroids: 2.11 beta-hydroxy series. J Med Chem 1987;30:1581-1588.
11. Bressinck R, Williams J, Peets E: Comparison of the effect of mometasone furoate ointment 0.1% and hydrocortisone ointment 1% on adrenocortical function in psoriasis patients. Today's Ther Trends 1988; 5:254-265.
12. Katz HI, Prawer SE, Watson MJ, Scull TA, Peets EA: Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis: Atrophogenic potential. Int J Dermatol 1989;28:342-344.
13. Medansky RS, Bressinck R, Cole GW, Decken JH, Ellis CN, Guin JD, Herndon JH, Lasser AE, Leibsohn E, Menter MA: Mometasone furoate ointment and cream 0.1% in treatment of psoriasis: Comparison with ointment and cream formulations of fluocinolone acetonide 0.025% and triamcinolone acetonide 0.1%. Cutis 1988;42:480-485.
14. Swinehart JM, Barkoff JL, Dvorkin D, Fisher G, Peets EA: Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis. Int J Dermatol 1989;28:680-681.
15. Vanderploeg DE, Cornell RC, Binder R, Weintraub JS, Jarrat M, Jones ML, Peets EA: Clinical trial in scalp psoriasis: Mometasone furoate lotion 0.1% applied once daily vs. betamethasone valerate lotion 0.1% applied twice daily. Acta Ther 1989; 15:145-152.
16. Vernon HJ, Lane AT, Weston W: Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991;24:603-607.
17. Boukamp P, Petrussevska RT, Breitkreuz D, Fusenig ND: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106:761-771.
18. Postlethwaite AE, Seyer JM, Kang AH: Chemotactic attraction of human fibroblasts to type I, II and III collagen and collagen-derived peptides. Proc Natl Acad Sci USA 1978; 75:871-875.
19. Wach F, Hein R, Adelmann-Grill BC, Krieg T: Inhibition of fibroblast chemotaxis by superoxide dismutase. Eur J Cell Biol 1987;44:124-127.
20. Mauch C, Hatamochi A, Scharfetter K, Krieg T: Regulation of collagen synthesis in fibroblasts within a three-dimensional collagen gel. Exp Cell Res 1988;178:493-503.
21. Belsito DV, Baer RL, Schultz JM, Thorbecke GJ: Relative lack of systemic effects of mometasone furoate on Langerhans cells of mice after topical administration as compared with other glucocorticosteroids. J Invest Dermatol 1988;91:219-223.